New NPIL unit to focus on innovations

Published: 6-Oct-2006
Ingredients

Pharma custom manufacturer NPIL Pharma (UK) has created a dedicated unit, NPIL Innovations - NPIL(i) - to develop and apply new technologies for faster, more cost effective process development and production of APIs. Initially it will focus its efforts in three main areas: biocatalysis, chemocatalysis and flow processing, said executive director Michael Fernandes.


Pharma custom manufacturer NPIL Pharma (UK) has created a dedicated unit, NPIL Innovations - NPIL(i) - to develop and apply new technologies for faster, more cost effective process development and production of APIs. Initially it will focus its efforts in three main areas: biocatalysis, chemocatalysis and flow processing, said executive director Michael Fernandes.

With a base in the UK and NPIL's new research centre in Mumbai, NPIL(i) will have a science and technical staff of 25, with an aim to double this to more than 50 within 18 months. It will be led by Ian Grundy, previously sales director for NPIL Pharma (UK). The new business unit will work with both in-house and external/licensed technologies.

The NPIL(i) mission will be to develop and apply the most competitive manufacturing route for a fine chemical, registered intermediate or API. The portfolio will include development of NPIL's new, catalyst-based racemisation technology SCRAM. NPIL(i) will look to build on Huddersfield's existing strong reputation in pharma technologies, including the award-winning CATHyeurožÂ¢ and CACHyeurožÂ¢ chiral technologies acquired by NPIL from Avecia.

'NPIL(i) is looking for step changes through technologies that can accelerate commercial production efficiencies for increasingly complex and costly pharma products. The clear objective is to find, test and harness technologies to solve customer production challenges,' said Grundy.

Already among the top 10 custom manufacturers in the world, NPIL Pharma is looking to move into the global top three players in pharma custom services. Creating NPIL(i) is part of its 'global footprint' strategy, integrating manufacturing capability in India with acquired European and North American centres of excellence in both early phase and commercial scale production technologies.

To date, key steps in this strategy have included the December 2005 acquisition of the ex-Avecia Pharmaceuticals business and the purchase in June 2006 of Pfizer's fully integrated API production and supply chain facility in Morpeth, UK.

See more

You may also like

Ingredients

FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars

Read more
The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Trending Articles

  1. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  2. Rousselot Rousselot is a global leader of gelatin and collagen-based solutions, serving the food, health & nutrition, biomedical, and pharmaceutical sectors. With our advanced Science & Innovation team, we unlock the secrets of the collagen molecule to create products that meet the highest standards of safety and quality. Through our state-of-the-art operations and extensive technical and formulation expertise, we help our customers achieve their goals, create world-class products, and we “Reach further together”. Rousselot is Darling’s Ingredients Health Brand.
  3. Debunking the myths of HPMC adoption Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
  4. Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
  5. Evonik increases plant-derived cholesterol supply The ingredient is used in the manufacture of mRNA vaccines and gene therapies

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Ingredients

FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars

The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Ingredients

Meet Navetta: new approach to safety testing of drugs and particles

Turn inhalation research upside down
Ingredients

Shimadzu’s new UV-1900i Plus – smarter, faster UV-Vis spectrophotometer

Next-generation model offers ultra-fast scans and versatile measurement modes
Ingredients

IMCD bolsters API portfolio with Trichem Healthcare acquisition

This acquisition will bolster IMCD's portfolio of specialty pharmaceutical ingredients
Ingredients

BASF opens US GMP Solution Centre in Michigan

Catered towards its biopharma and small molecule customers, the site will provide excipients and bioprocessing ingredients to the US market
Subscribe now